Company Valuation: Alaunos Therapeutics, Inc.

Data adjusted to current consolidation scope
Fiscal Period: December 2020 2021 2022 2023 2024 2025
Market Cap 1 536.6 234 155.4 16.98 3.05 7.209
Change - -56.4% -33.56% -89.08% -82.04% 136.32%
Enterprise Value (EV) 1 426.3 187.3 135.9 10.92 1.959 5.824
Change - -56.08% -27.43% -91.96% -82.06% 197.23%
P/E -6.61x -2.97x -3.74x -0.48x -0.65x -1.47x
PBR 4.35x 4.04x 4.03x 2.69x 1.48x 3.52x
PEG - 0.8x 0.1x 0x 0x 0.1x
Capitalization / Revenue - 587,819,588x 53,196,617x 3,396,281,000x 305,038,500x 1,441,761,400x
EV / Revenue - - - - - -
EV / EBITDA -5.38x -2.52x -4.53x -0.42x -0.41x -1.38x
EV / EBIT -5.31x -2.44x -4.15x -0.38x -0.41x -1.38x
EV / FCF -11.8x -5.36x -4.86x -2.14x -0.59x -7.73x
FCF Yield -8.45% -18.7% -20.6% -46.7% -168% -12.9%
Dividend per Share 2 - - - - - -
Rate of return - - - - - -
EPS 2 -57.22 -55.1 -26.06 -22 -2.922 -2.198
Distribution rate - - - - - -
Net sales - 0.398 2.922 0.005 0.01 0.005
EBITDA 1 -79.23 -74.21 -29.98 -26.18 -4.81 -4.218
EBIT 1 -80.36 -76.81 -32.74 -28.49 -4.812 -4.225
Net income 1 -79.98 -78.75 -37.73 -35.14 -4.679 -4.176
Net Debt 1 -110.3 -46.69 -19.55 -6.062 -1.091 -1.385
Reference price 2 378.000 163.500 97.365 10.605 1.905 3.230
Nbr of stocks (in thousands) 1,420 1,431 1,596 1,601 1,601 2,232
Announcement Date 01/03/21 30/03/22 07/03/23 01/04/24 31/03/25 31/03/26
1USD in Million2USD
Estimates

P/E (Y) EV / Sales (Y) EV / EBITDA (Y) Dividend Yield (Y) Capi.($)
- - - - 5.16M
21.75x6.73x14.72x1.46% 57.82B
32.16x8.12x25.19x0.06% 53.71B
-43.06x13.69x-40.15x-.--% 23.8B
-18.33x4.37x-7.66x-.--% 23.26B
25.89x5.11x13.48x-.--% 20.7B
24.77x4.84x15.78x-.--% 17.81B
50.68x20.65x53.17x0.07% 16.9B
-560.54x39.3x-4381.59x-.--% 16.36B
17.45x5.07x11.8x-.--% 13.96B
Average -49.91x 11.99x -477.25x 0.18% 24.43B
Weighted average by Cap. -22.75x 10.26x -282.34x 0.36%

Y-o-Y evolution of P/E

Historical PBR trend

Evolution Enterprise Value / Sales

Change in Enterprise Value/EBITDA

  1. Stock Market
  2. Stocks
  3. TCRT Stock
  4. Valuation Alaunos Therapeutics, Inc.